Patent intelligence · US
US 11634482
Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer
Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer
Patent details — US 11634482
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 25, 2023
- Expiration
- Apr 20, 2043
- Applicant
- Julius-Maximilians-Universitat Wurzburg
- Claims
- 15
- CPC classes
- A61K, A61K2039/505, A61K39/395, A61K39/39533
Quick answer
US 11634482 (Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer) is held by Julius-Maximilians-Universitat Wurzburg. Status: granted. Granted Apr 25, 2023. Expires Apr 20, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Julius-Maximilians-Universitat Wurzburg
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K2039/505, A61K39/395, A61K39/39533, A61K39/3955, A61P
More from Julius-Maximilians-Universitat Wurzburg
Related pharmaceutical patents in our USPTO index.
-
US 12391732
Articles comprising a silk polypeptide for antigen delivery
granted -
US 12379385
Methods of treating patients afflicted with irritable bowel syndrome, inflammatory bowel disease or chronic gastrointestinal functional disorders based on assessment of intestinal barrier function
granted -
US 12318397
Methods and compositions for testosterone production
granted -
US 12290524
Methods and compositions for testosterone production
granted -
US 12171837
Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates
granted -
US 12168718
Thermogelling supramolecular sponge as self-healing and biocompatible hydrogel
granted -
US 12144876
Security mechanisms for radiopharmaceutical elution system and elution process
granted -
US 12133890
Antigen-binding polypeptide targeting B7H3 and application thereof
granted
Frequently asked questions
What is US patent 11634482?
US 11634482 (Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia and cancer) is held by Julius-Maximilians-Universitat Wurzburg. Status: granted. Granted Apr 25, 2023. Expires Apr 20, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11634482?
Julius-Maximilians-Universitat Wurzburg is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 138 pharmaceutical patents for this assignee.
When does US 11634482 expire?
Our index shows an expiration date of Apr 20, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.